The 13-valent pneumococcal conjugated vaccine introduction in subjects aged> 50 years: the result of a Health Technology Assessment

Flavia Kheiraoui, Chiara De Waure, Maria Lucia Specchia, Maria Luisa Di Pietro, L Mantovani, Silvio Capizzi, Chiara Cadeddu, Francesco Di Nardo, Anna Maria Ferriero, Maria Assunta Veneziano, G Furneri, Maria Rosaria Gualano, Nicola Nicolotti, Antonella Sferrazza, Pietro Refolo, Maria Daniela Gliubizzi, R Saulle, Giuseppe La Torre, Walter Ricciardi

Risultato della ricerca: Contributo in rivistaArticolo in rivista

Abstract

Streptococcus pneumoniae (Spn) is a common cause of Community-Acquired Pneumonia (CAP) and Invasive Pneunmococcal Diseases (IPD). Risk for infection increases in particular in elderly. The aim of the study was to evaluate the introduction of 13-valent conjugate pneumococcal vaccine (PCV13) among patients ≥50 years.
Lingua originaleEnglish
pagine (da-a)284-285
Numero di pagine2
RivistaEuropean Journal of Public Health
DOI
Stato di pubblicazionePubblicato - 2013

Keywords

  • health technology assessment

Fingerprint

Entra nei temi di ricerca di 'The 13-valent pneumococcal conjugated vaccine introduction in subjects aged> 50 years: the result of a Health Technology Assessment'. Insieme formano una fingerprint unica.

Cita questo